secwatch.observer — SEC 8-K summary
======================================

Issuer:     Raphael Pharmaceutical Inc. (RAPH)
CIK:        0001415397
Form:       8-K
Filed at:   2022-07-07T23:59:59+00:00
Accession:  0001213900-22-037819
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 4.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Raphael Pharma dismisses Deloitte auditor, Chairman Press resigns; new exec comp agreements
--------------------------------------------------------------------------------

- Dismissed Brightman Almagor Zohar (Deloitte) as auditor; appointed Weinstein International as new independent auditor.
- Chairman Prof. Joseph Press resigned from board effective June 30, 2022; consulting fee $1,000/meeting, 280k shares, 105k warrants at $1.12.
- CEO Shlomo Pilo (Sheffa Enterprises) gets new management agreement: $10k/mo (2022) then $20k/mo, 1M warrants at $1.12, expires Dec 2024.
- CFO Guy Ofir gets operations agreement: $6k/mo (2022) then $12k/mo, 1M restricted shares, 1M warrants at $1.00, expires Dec 2024.
- CTO Dr. Igal Louria Hayon: $9k/mo (2022) then $12k/mo, 990k warrants at $0.01, plus 15% of royalties from cannabis COVID and RA indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1415397/000121390022037819/0001213900-22-037819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1415397/000121390022037819/ea162555-8k_raphael.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-037819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer